I-J U Wu1, Jia-Huei Tsai2, Cheng-Maw Ho3. 1. Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan. 2. Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. 3. Department of Surgery, National Taiwan University Hospital, 100, Taipei, Taiwan. miningho@ntu.edu.tw.
Abstract
BACKGROUND: Amiodarone is an antiarrhythmic drug that has been recognized to induce hepatotoxicity. We report a case of acute-on-chronic liver failure (ACLF) in a patient who was receiving amiodarone for more than 2 years. The patient developed cirrhosis and suppurative microabscesses of the liver and died of progressive liver failure. CASE PRESENTATION: A 69-year-old woman with risk factors for nonalcoholic fatty liver disease (NAFLD) was treated with oral amiodarone at a daily dose of 400 mg for more than 2 years, until she developed epigastralgia and vomiting. Initial laboratory findings included leukocytosis and elevated liver enzymes. Images of abdominal computed tomography scan revealed diffusely increased hepatic attenuation density (in contrast to decreased density in NAFLD), hepatomegaly, periportal edema, and ascites. Liver biopsy targeting the hotspot identified through positron emission tomography confirmed the diagnosis of amiodarone-associated chronic steatohepatitis and superimposed microabscesses. The patient died of progressive ACLF despite intensive supportive care. CONCLUSION: Accumulation of amiodarone can result in chronic liver disease and pose an additional risk of ACLF following infection.
BACKGROUND:Amiodarone is an antiarrhythmic drug that has been recognized to induce hepatotoxicity. We report a case of acute-on-chronic liver failure (ACLF) in a patient who was receiving amiodarone for more than 2 years. The patient developed cirrhosis and suppurative microabscesses of the liver and died of progressive liver failure. CASE PRESENTATION: A 69-year-old woman with risk factors for nonalcoholic fatty liver disease (NAFLD) was treated with oral amiodarone at a daily dose of 400 mg for more than 2 years, until she developed epigastralgia and vomiting. Initial laboratory findings included leukocytosis and elevated liver enzymes. Images of abdominal computed tomography scan revealed diffusely increased hepatic attenuation density (in contrast to decreased density in NAFLD), hepatomegaly, periportal edema, and ascites. Liver biopsy targeting the hotspot identified through positron emission tomography confirmed the diagnosis of amiodarone-associated chronic steatohepatitis and superimposed microabscesses. The patient died of progressive ACLF despite intensive supportive care. CONCLUSION: Accumulation of amiodarone can result in chronic liver disease and pose an additional risk of ACLF following infection.
Entities:
Keywords:
Acute-on-chronic liver failure; Amiodarone; Case report; Microabscess; Steatohepatitis
Authors: L Miele; A Liguori; G Marrone; M Biolato; C Araneo; F G Vaccaro; A Gasbarrini; A Grieco Journal: Eur Rev Med Pharmacol Sci Date: 2017-03 Impact factor: 3.507
Authors: Evangelos Triantafyllou; Kevin J Woollard; Mark J W McPhail; Charalambos G Antoniades; Lucia A Possamai Journal: Front Immunol Date: 2018-12-14 Impact factor: 7.561
Authors: Cornelius Engelmann; Karen Louise Thomsen; Nekisa Zakeri; Mohammed Sheikh; Banwari Agarwal; Rajiv Jalan; Rajeshwar P Mookerjee Journal: Crit Care Date: 2018-10-10 Impact factor: 9.097